A Phase 1b study of Psilocybin Assisted Psychotherapy to address fear of recurrence in patients diagnosed with early-stage breast cancer and ovarian cancer in remission
Measure the primary effect of psilocybin assisted psychotherapy on fear of recurrence.
Why this Research Matters
A study conducted to determine if a single dose of 25 mg. of psilocybin, in combination with therapy, will address fear of recurrence in patients diagnosed with early-stage breast cancer and ovarian cancer in remission
Who can Participate
Female adults with early-stage breast cancer or late-stage ovarian cancer who have a fear of recurrence. **Target population: Adult females with early-stage (stage 1 or 2) breast cancer or late-stage (stage 3 or 4) ovarian cancer in remission who may have recently completed surgery or chemotherapy **General overall ability to function and care for self **Fear of cancer recurrence (eligible survey score at first two study visits) **Have an identified support person **Additional eligibility criteria will be determined by a healthcare provider at the first two study visits
Study ID
Protocol Number: 23-1455
More information available at ClinicalTrials.gov: NCT06430541
Meet the Team
Principal Investigator